Stengone Carmine N. sold $40K of CTNM
Stengone Carmine N. (CEO and President) sold 2,500 shares of Contineum Therapeutics, Inc. (CTNM) at $16.01 on 2026-08-03 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The newest disclosed fact is the CEO’s open-market sale of 2,500 shares at $16.0116 under a pre-arranged 10b5-1 plan.
Market read
Primarily a routine insider-sale datapoint; limited standalone trading signal due to 10b5-1 pre-arrangement.
What to watch
Traders may want to compare this sale size and frequency to prior Form 4 activity and the company’s recent news flow, which is not provided here.
Background
The article is an SEC Form 4 insider transaction disclosure for Contineum Therapeutics, Inc. (CTNM).
Ticker impact
Contineum Therapeutics CEO and President Stengone Carmine N. sold 2,500 shares on 2026-08-03 at $16.0116, per Form 4.
Low near-term impact; any reaction is likely muted unless traders suspect plan timing or unusual size versus prior activity.
The filing is a primary SEC Form 4 disclosure, but it specifies a pre-arranged 10b5-1 plan, reducing interpretive weight for directional forecasting.
Market effects
No clear sector read-through from a single 10b5-1 insider sale.
None indicated.
None indicated.
Counterpoint
A 10b5-1 sale can still coincide with internal liquidity needs or diversification, so it may not reflect bearish fundamentals.
Key entities
- issuerContineum Therapeutics, Inc.
Subject of the Form 4 insider transaction disclosure.
- insiderStengone Carmine N.
CEO and President who executed the reported sale.
